Image Credit: www.utunisphere.com
October 1, 2018
The Unisphere Opens in Silver Spring to Grow Transplantable Organs with a Net Zero Carbon Footprint
On Friday, September 21st United Therapeutics celebrated the Grand Opening of the highly anticipated Unisphere building in Silver Spring. Beyond the normal excitement that a growing biotech company in Maryland brings is the work that will be done here. The new facility will be dedicated to managing the development of an unlimited supply of transplantable organs. This emerging, cutting-edge field of organ manufacturing is one that the company aims to be a world leader in and this new facility marks an important step forward to that goal.
The “Unisphere,” now claims the valiant recognition as the largest Net Zero commercial building in the US. Architect and Engineering firm, EwingCole, and Contractor, Whiting-Turner, built the Unisphere using advanced building technologies and sustainability practices to achieve this Net Zero status (learn more), which means that the site will have absolutely no carbon footprint from operations.
The 210,000 square-foot, symbolically egg-shaped “Unisphere,” will add 120,000 SF of new office space, 10,000 SF of retail space, in addition to some public amenity space accessible to the Silver Spring community. The building will be occupied by clinical operations for pulmonary disease, heart failure, and organ transplantation as well as In Silico molecular biology, which is a virtual drug development lab.
The 1000 Spring Street facility marks the fourth expansion for United Therapeutics since 2006, further establishing the company as one of the largest biopharmaceutical companies in the BioHealth Capital Region, now occupying 435,000 square feet of office and lab space in Silver Spring.
The evening affair included tours of the new building, musical performances, speeches from Jared Loos, CEO of EwingCole, County Executive Ike Leggett, a keynote speech by J. Craig Venter and final remarks and ribbon cutting by United Therapeutics CEO, Martine Rothblatt.
United Therapeutics shared a video on LinkedIn recapping the evening’s events.
United Therapeutics Corporation is biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The wholly-owned subsidiary, Lung Biotechnology PBC, is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply.
For more on the United Therapeutics Organ Manufacturing Group visit http://omg.unither.com/
For more information visit United Therapeutics’ BioBuzz Company Page and follow them to get weekly news delivered to your inbox.
Chris Frew, @biotechmd
Latest posts by Chris Frew (see all)
- Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
- D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021
- RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer - October 5, 2021
- Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases - September 30, 2021
- Cartesian Therapeutics to double footprint, headcount in Gaithersburg - September 30, 2021